Fig. 2.
Fig. 2. Molecular follow-up of myeloma patients who achieved serologic and clinical CR after TX1 or TX2. / Nos. 1 to 8 and 9 to 13 represented double autotransplants supported with PBSC or CD34+ cells, respectively, whereas Nos. 14 and 15 were patients who were submitted to a single course of high-dose therapy with unmanipulated stem cells.

Molecular follow-up of myeloma patients who achieved serologic and clinical CR after TX1 or TX2.

Nos. 1 to 8 and 9 to 13 represented double autotransplants supported with PBSC or CD34+ cells, respectively, whereas Nos. 14 and 15 were patients who were submitted to a single course of high-dose therapy with unmanipulated stem cells.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal